Welcome to our dedicated page for Bluejay Diagnostics SEC filings (Ticker: BJDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bluejay Diagnostics filings document the company’s medical diagnostics business, Nasdaq-listed common stock, and disclosures tied to development of the Symphony™ near-patient testing platform. Form 8-K reports cover corporate updates, financial condition items, Regulation FD disclosures, SYMON clinical-study updates, conference-related product disclosures, manufacturing readiness, and capitalization matters involving warrants and private placements.
The company’s proxy materials describe annual meeting proposals, voting procedures, board and governance matters, and stockholder approval topics. Bluejay’s filings also identify it as an emerging growth company and include formal disclosures on material agreements, registered securities, risk-relevant development activities, and capital-structure changes such as reverse stock splits and warrant exercises.
Bluejay Diagnostics director Wurth Douglas Clark bought additional common stock in the company. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics, Inc. common stock from the issuer in a private placement at $2.00 per share.
Following this transaction, his reported holdings increased to 12,608 shares of common stock, which includes 34 shares held by Wurth Holdings LLC, an entity he controls.
Bluejay Diagnostics, Inc. director and President/CEO Indranil Dey bought additional company stock. On March 14, 2026, he purchased 12,500 shares of common stock from the company in a private placement at $2.00 per share, bringing his direct holdings to 12,522 shares. He also indirectly owns 127 shares held by Lana Management & Business Research International, LLC, over which he has voting and dispositive power.
Bluejay Diagnostics director Donald R. Chase increased his stake by buying shares directly from the company. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics, Inc. common stock in a private placement at $2.00 per share, a total investment of $25,000. After this transaction, he directly owns 12,525 common shares of the company.
Bluejay Diagnostics director Fred S. Zeidman bought additional shares of the company’s stock. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics common stock from the company in a private placement at $2.00 per share. Following this transaction, he directly owns 12,500 common shares.
Bluejay Diagnostics director Svetlana Dey bought additional company stock. On March 14, 2026, she purchased 12,500 shares of Bluejay Diagnostics common stock from the company in a private placement at $2.00 per share.
After this transaction, Ms. Dey directly owns 12,501 common shares and indirectly controls 127 common shares held through Lana Management & Business Research International, LLC, over which she has voting and dispositive power.
Bluejay Diagnostics, Inc. had a Schedule 13G/A filing showing Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 51,061 shares, representing 4.99% of the company's common stock (as of 03/31/2026). Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., reports shared voting and dispositive power over these shares; the Master Fund is the direct holder. Steven Boyd is identified as the managing member of Armistice Capital and is included in the joint filing.
Bluejay Diagnostics, Inc. reported a net loss of $1.9 million for the quarter ended March 31, 2026, similar to the prior year, with operating expenses of about $1.9 million split between research and development and general and administrative costs.
The company ended the quarter with $3.7 million in cash and cash equivalents and current liabilities of $1.4 million, and estimates its cash will fund operations only through the third quarter of 2026. Management discloses substantial doubt about its ability to continue as a going concern and expects to need at least $20 million in additional capital by the end of 2027 to pursue FDA clearance of its Symphony IL‑6 sepsis test.
Bluejay continues a pivotal SYMON‑II sepsis study and cartridge manufacturing work with contract manufacturer Sanyoseiko, but notes that failure to secure financing could force it to delay or abandon its regulatory strategy and potentially pursue liquidation, in which common stockholders may recover little value.
Bluejay Diagnostics, Inc. provided a first quarter 2026 corporate and financial update focused on its Symphony near-patient diagnostic platform for sepsis care. The company highlighted ongoing clinical, manufacturing, and regulatory work to advance its investigational Symphony IL-6 test, including continued enrollment momentum in the pivotal SYMON-II study.
As of March 31, 2026, Bluejay reported cash and cash equivalents of approximately $3.7 million. Net loss was approximately $1.9 million for the first quarter of 2026, roughly in line with the same period in 2025. Symphony and the IL-6 Test remain investigational and not yet cleared by the U.S. Food and Drug Administration.
Bluejay Diagnostics, Inc. is asking stockholders to approve several proposals at its June 9, 2026 annual meeting. Stockholders will vote to elect five directors, authorize a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑20, and amend the 2021 Stock Plan to add 600,000 shares for equity awards. They will also vote on ratifying Wolf & Company, P.C. as auditor for 2026 and may consider other proper business. As of April 28, 2026, 1,034,715 common shares were outstanding, each carrying one vote.
Bluejay Diagnostics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders and asks holders to consider five proposals, including reelecting five directors, approving a reverse stock split (range: 1-for-2 to 1-for-20) via an amendment to the charter, increasing the 2021 Stock Plan share reserve, and ratifying Wolf & Company, P.C. as auditor. The record date for voting is April 28, 2026, and the proxy materials and the 2025 Annual Report on Form 10-K are available at the posted link. The board recommends voting FOR each proposal; the Board retains discretion to select the final reverse-split ratio (subject to a minimum public float constraint) and may abandon the split even if approved.